We’re honored to be named an IDEA Pharma “Disruptive Pioneer” in the 2026 Innovation & Invention Index, recognizing the potential of MGDs to drug historically undruggable targets. Thanks to @statnews.com, Allison DeAngelis, and @matthewherper.bsky.social for the coverage: bit.ly/49Gcwyk

We look forward to participating in two upcoming investor conferences – the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference in New York. Learn more: bit.ly/4tRW7OB

Join Georg Petzold and Chao Quan for an @endpts.com Webinar on Tuesday, May 12 at 10:30am EDT exploring the surprising versatility of molecular glue degraders and the different ways cereblon can engage its targets. To register: bit.ly/4ugCDDV

Today, we report financial results and business highlights for the first quarter 2026. CEO Markus Warmuth shares his perspective on the progress behind these results and the momentum across our pipeline. Read more: bit.ly/3P0tv7v

Monte Rosa’s Chief Data & Information Officer, John Castle, is presenting at the Swiss Biotech Showcase this week in Basel – sharing how we’re advancing our pipeline and expanding molecular glue degraders to address previously undruggable targets. If you’re attending, we look forward to connecting.

ICYMI: We shared preclinical data on our CCNE1-directed MGD at #AACR26, highlighting a potential first-in-class approach to a frequently amplified driver oncogene. We believe MRT-55811 has the potential to provide clinical benefit across CCNE1-amplified cancers: bit.ly/4eHzTe2

We’re presenting preclinical data at #AACR26 on the potential of our CCNE1-directed molecular glue degrader to treat CCNE1-amplified solid tumors, suggesting a potential new approach to a historically undruggable target. Learn more: bit.ly/48dRoil

We’re hitting the road and heading to #AACR2026. There, CEO Markus Warmuth will join a panel of biopharma leaders pioneering proximity-induced therapies: bit.ly/4te6LQ2

Maciej Cabanski presents today at the 20th WRIB on biomarker modalities in the early development of MGDs for immune mediated diseases and oncology, highlighting advances in clinical biomarker strategies for targeted protein degradation.

We’re delighted to have volunteered with Science Club for Girls this month, supporting their mission to increase access to STEM education and empower the next generation of girls and gender-expansive youth to see themselves in science.

Today, we report business highlights and financial results for the fourth quarter and full year of 2025. Read more: bit.ly/47240Zf

Jonathan Grinstein of Inside Precision Medicine had a wide-ranging conversation with our CEO, Markus Warmuth, for the “Behind the Breakthroughs” podcast, highlighting how we expect 2026 to be a breakthrough year for Monte Rosa and molecular glue degraders.

Filip Janku, CMO, will field questions on Monte Rosa’s progress and programs during a fireside chat today at the Barclays 28th Annual Global Healthcare Conference. We hope you can join us! bit.ly/4umolCx

Autoimmune diseases affect millions, yet many individuals still lack effective treatment options. At Monte Rosa, we’re harnessing MGDs to expand what’s possible in autoimmune care. Learn more this Autoimmune Awareness Month: bit.ly/409ianC

Our CEO, Markus Warmuth, will provide an overview on recent progress and clinical data from our pipeline programs, including our NEK7 and GSPT1-directed degraders, today at the TD Cowen Health Care Conference. bit.ly/3OAtyXb

We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream. Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.

CMO, Filip Janku, comments on our updated MRT-2359 data, which supports initiation of a new Phase 2 study this year to evaluate MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations. bit.ly/4aO3E9B

Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). bit.ly/4aPUt8P

It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.

On International Day of Women and Girls in Science, we’re celebrating the individuals advancing scientific innovation. From Boston to Basel, women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: bit.ly/4krQLX8 #February11

ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide, yet many are unfamiliar with it. Caused by plaque buildup in the arteries, it can lead to heart attack and stroke. This Heart Health Month, learn more from @americanheart.bsky.social: bit.ly/3LCK8o7

On #WorldCancerDay, we’re proud to stand #UnitedByUnique. At Monte Rosa, our paths into oncology may differ, but we’re united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: bit.ly/4qfnEHW

ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @keystonesymposia.bsky.social for convening such a rich and engaging event. View the presentation here: bit.ly/4bk9dP0

We present findings today at #KSAutoimmune26 highlighting VAV1’s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases, including SLE, Sjögren’s disease, rheumatoid arthritis, IBD, and others.

New findings in @natsmb.nature.com challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce ‘glueprints’ as a new way to potentially expand the MGD target space: go.nature.com/4jP23EJ

CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study. Read the full data release here: bit.ly/4pxGtWz

Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz

Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.

In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations. Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.

In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations. Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.

This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.

Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. bit.ly/3KL2raf

We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. Access the webcast here: bit.ly/3KSVjbQ

Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development: bit.ly/3KvGUlL

Our invited review in @cp-trendsbiotech.bsky.social is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues. Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g

Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference, where he’ll share insights on Monte Rosa and the progress of our molecular glue degraders. To register: bit.ly/44I2dam

Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk

ICYMI, this year we were thrilled to be named “Biotech of the Year” at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting, and congratulations to our entire team.

In London for the Jefferies Global Healthcare Conference, or following along virtually? Join our CEO, Markus Warmuth, for a fireside chat as he reviews the latest on our pipeline programs. Register or view the webcast: bit.ly/3X0oso4

Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio. Register or view the webcast: bit.ly/4p8Inx1

ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases. Learn more: bit.ly/3XjONNQ

CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference. To register: bit.ly/4qIpZwq

Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025. Learn more: bit.ly/43SJQiF #AHA2025

Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo

ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings. View the poster: bit.ly/3L955q7

At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases. Read the full press release here: bit.ly/4o7koyf

Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social. Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye

Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf

David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB

This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs. CEO Markus Warmuth comments: bit.ly/3Vl0yTg